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     To prevent recurrence of pterygium after surgical repair, topical application of mi-
tomycin C has been prescribed in Japan since 1962. Various reports of severe scleral 
changes following this treatment began to appear in 1965. We now report 9 such cases, 
3 men and 6 women within the age range from 48 to 73 years. 
     In these patients, the pterygium was excised using the bare scleral technique and 
mitomycin C was instilled postoperatively. The duration of topical application and the 
number of instillations varied. The period from operation to onset of scleral lesion was 
between one month and 10 years. Although the mechnisms of toxicity remain to be deter-
mined, the ophthalmologist should be aware that when mitomycin C is being instilled, 
scleral lesion may appear even after a long postoperative course.
                  INTRODUCTION 
     The major problem in the treatment of pterygium is to prevent recurrences after 
surgical excision. Even in cases of total excision of diseased tissues, there are recur-
rences, for example, when the corneal epithelium fails to cover the bare limbus, before 
the conjunctival tissues with granulation and neovascularization reach the limbal area. 
Consequently, the radiation therapy prescribed shortly after the surgery is often most 
effective. As cataracts sometimes develop or the sclera is damages after radiation therapy, 
the anti-neoplastic drugs, thiotepa and mitomycin C are clinically prescribed. 
     In 1962, KUNITOMO and MORI14) reported that the pterygium could be treated 
with topical application of mitomycin C solution, however, reports of severe scleral dam-
ages induces by this treatment began to appear since 19657)9) 10)19)21)22)24)25)27)28)29)31)-35)
[-I, 5 p --
As there is little documentation of such complications in the English literature, the 
findings of toxicity in 9 patients are described herein. 
               PATIENTS AND METHODS 
      The nine patients with scleral lesion after previous pterygium treatment were all 
referred to the Ophthalmology Clinic of Nagasaki University School of Medicine. These 
3 men and 6 women, within the age range from 48 to 73 years had undergone pterygium 
removal by the bare scleral technique and mitomycin C was instilled postoperatively. 
The duration and number of instillations varied with each patient. The period from 
operation to onset of scleral lesion was between one month and 10 years. 
      Mitomycin C is an anti-tumor antibiotic complex of blue violet crystals produced 
by a strain of streptomyces caespitosis from clay in Tokyo, by HATA and associates')") 
in 1956. 
     Originally 0.4 mg/ml mitomycin C solution dissolved in 5 % glucose was pre-
pared14) , but 1 mg/ml solution (Case 7), 0.8 mg/ml solution (Case 6) and 0. 2 mg/ml 
solution (Case 9) were also applied. 
                     RESULTS 
     As shown in Table 1, the scleral lesion due to mitomycin C instillation included 2 
cases of scleral thinning (Case 3, 5. Fig. 1), 2 cases of scleral ulcer (Case 7, 9. Fig. 
2) and 5 cases of scleral calcification (Case 1, 2, 4, 6, 8. Fig. 3). In all these cases, 
medication was started immediately or within a couple of days after surgery. The number 
of instillations varied, that is, every 2 hours (Case 2), once a day (Case 5) 3 times a 
day (Case 3, 6, 8, 9) and 4 times a day (Case 1, 4, 7). The period from operation to 
onset of scleral lesion was between one month and 10 years. 
     Cases of early onset (Case 5, 7, 9.) were observed within one month, and in each, 
the scleral ulcer was of moderate size. Cases 5 and 7 were patients who had previous 
surgery for pterygium and the Case 9 patient was prescribed mitomycin C instillations 
for one month. Especially in Case 7, symptoms occurred 2 weeks postoperatively and 
regressed after 4 months but severe symptoms were observed again after 20 months. 
Here, scleral homograft and covering of conjunctiva had to be done. The prognosis 
was good in those with an early onset. 
     Cases of later onset (Cases 1, 2, 3, 6, 8) occurred after one year or longer. The 
symptoms were severe and scleral homograft and covering of conjunctiva had to be done. 
The relationship between the number and duration of instillations and development of 
scleral lesion could not be clearly defined because the eye lotions had been administrated 
by the patients themselves. 
     Calcification of the sclera occurred in 5 out of these 9 patients and a histopatho-
logical study") was done on tissues from the Case 2 patient.
                  Table I Scleral Lesion Following Administration of Mitomycin C after Surgery for Pterygium 
                             Operation to Mitomycin C                                         Subjective Clinical  C
ase Age Sex Laterality Onset Complaints Solution Instillation Complications Management Prognosis 
                              (months) -Density-
                                           headache calci-   1 73 F L 16 0
, 4mg/ml 4/day fication resection of good (Ref. 32) ocular pain 2 WK or more iridocyclitis calcification 
                                           foreign body scleral calci-   2 
57 F R 12 sensation 0.4mg/ml 3/day fication iridencleisis enucleation (Ref. 32) ocular pain 11 days iridocyclitis 
                                                                                                   sec. glaucoma
                                       L) red eye R) thinning of3 R 3/d
ay sclera topical L) 
(Ref. 32) 51 M L 16 ocular pain 0.4mg/ml reduced vision 11 days L) Descemeto- antibiotics perforation 
                                                                                          cele. iritis 
   4 foreign body 4/da iridocyclitis s graft 1 homo 
(Ref. 34) 65 F L 3 sensation 0.4mg/ml 5 days scleral calci- gcovering of cataract                                            red eye fication 
                                                                                                          conjunctiva
   5 * red eye 1/day iritis covering of 
(Ref. 34) 60 M R 1 ocular pain 0.4mg/ml 2 days syn. post conjunctiva good                                                                                    cleral thinning 
                                                                       3/day iridocyclitis scleral homo-   6 
i red eye 0.8mg/ml 8 days 
(Ref. 34) 56 F R 120 ocular pain 0.4mg/ml 3/day scleral calci- graft covering good 
                                                                         4 days fication of conjunctiva 
           * photophobia I iritis scleral homo-   7 F R 1 f
oreign body lmg/ml 4-5/day corneoscleral- graft covering good (Ref. 34) 67 sensation 3 days ulcer of conjunctiva 
                                                                                    iridocyclitis covering of8 
56 F L 54 headache 0.4mg/ml 1/day scleral calci- conjunctiva necrotizing (Ref. 34) ocular pain 3 days fication scleral homo- scleritis 
                                                                                              graft 
                                                                                                      scleral homo-
Ref. 334) 48 M R 1 epiphora 0.2mg/ml 3/day scleral ulcer graft covering good ( ) of conjunctiva 
             * Recurrent pterygium
Figure 1. Scleral thinning and perforation. Case 3. 
         (From Yamanouchi and Mishima [32) )
Figure 2. Scleral ulcer. Rose bengale stain. Case 9. 
         (From Yamanouchi et al. [34) )
Figure 3. Scleral calcification (arrows). Case 2. 
         (From Yamanouchi [33) )
Figure 4. Sharp demarcated calcification of Case 2. 
         H-E stain. (From Yamanouchi [33))
      Case 2. The patient was a healthy 57-year-old Japanese woman who underwent 
surgery for pterygium of the right eye on January 27, 1965, and was treated with mito-
mycin C instillation 3 times daily for 11 days. On January 27, 1966, she complained of 
a foreign body sensation and pain in the right eye. Her condition was diagnosed as 
secondary glaucoma and she was referred to our clinic. On admission, scleral calcifica-
tion of the medial limbal sclera was evident (Fig. 3). Iridencleisis was performed but 
ocular tension remained elevated and finally the eyeball had to be enucleated. Micro-
scopic examination showed a sharp demarcated calcification area. There was no evidence 
of inflammation (Fig. 4). 
     Therapy : It is difficult to determine the onset because scleral lesion due to mito-
mycin C progresses insidiously and sometimes appears a long time after the surgery. If 
the scleral lesion is superficial, instillation therapy of antibiotics and antiinflammatory 
agents may be effective. If the focus is deep, the full thickness of the sclera should 
be resected with a portion of the surrounding healthy sclera and the defect restored with 
supplemental materials. These materials can be preserved human sclera, fascia lata, 
periosteum, conjunctiva and TENON capsule, buccal mucous membrane, auricular car-
tilage, and so on. We used preserved human scleral homograft in 6 cases and favorable 
results were obtained in 5. In Case 8, the scleral necrosis had extended all round the 
sclera and corneal ulcer developed. 
                    DISCUSSION 
     To prevent regrowth of the pterygium, radiotherapy (X-ray, radon, radium and 
strontium 90) have been prescribed3>4>s>MM30). The use of anti-neoplastic drugs gradually 
was favored as radiotherapy sometimes leads to formation of cataracts. Both irradiation 
and anti-neoplastic drugs are effective against rapidly growing neoplastic tissue, partic-
ularly the endothelium of newly formed blood vessels. 
     With regard to the pathological aspect of recurrence after pterygium excision, the 
first factor is neovascularization into the cornea from the limbus and the second is early 
junction formation between the corneal and conjunctival epithelia. This junction forms 
granulation tissue near the limbus area. 
     Thiotepa which was used before the development of mitomycin C is a anti-neoplastic 
alkylating agent of the nitrogen mustard family. It has an active antimitotic effect on 
rapidly growing cells and few side effects. The conception of the topical application of 
anti-neoplastic drugs was based on LANGHAM's report") that thiotepa inhibited the 
corneal vascularization in alloxanized rabbit eyes. Thiotepa has been used in low con-
centrations such as 1:2000 dilution and has produced clinical effectiveness for the post-
operative treatment of pterygium. This solution is applied several times a day for 6 to 
9 weeks postoperatively. Usually these are no signs of irritation or recurrence during 1 
to 3 years follow-up. 
     MEACHAM18> was the first to report the use of thiotepa in the prevention of re-
current pterygium in 1962 and many cases were reported') 5)11)13)14)16)18). The recurrent 
rates in these reports are summarized on the Table 2. 
     KUNITOMO and MORI14) was the first to prescribe mitomycin C to inhibit the 
recurrence after pterygium removal, in 1962. They found mitomycin C to be a non-
irritating agent and more effective than thiotepa in inhibiting granulation formation. 
Thereafter mitomycin C has been widely used in Japan and to date there are no reports 
of scleral lesion. But lesions due to mitomycin C have been reported')') 10)12)19)21)22)24)25) 
28)29)31)32)-34)36) by inches . 
     Pterygium recurs in over 30 % of various types of excisions. With the use of 
beta irradiation and topical application of anti-neoplastic drugs, the recurrence rates 
were considerably reduced. 
     According to MORI et al. 2°) , the recurrence rate was 13 %, using mitomycin C 
solution. YAMASHITA and ADACHI35) reported that the recurrence rate was 39 %, 
using mitomycin C, as compared with 43 % in control eyes. However, there are only a 
few summarized data on mitomycin C treatment after pterygium surgery, as shown on 
Table 2, and the problem of late complications remained. 
     In beta irradiation after pterygium surgery, the occurrence of scleral necrosis 
or scleral deep ulceration, albeit rare, has been reported : CAMERON 19723), CAPPIN 
19735), TARR and CONSTABLE 1980"), MATSUDA 198117) and NOSHIRO 198111). As 
for mitomycin C instillation, KUNITOMO and MORI14) reported no incidence of serious 
eye lesions in their patients. Later MORI21) described patients with scleromalacia per-
forans or necrotizing scleritis due to mitomycin C instillation and he proposed that systemic 
disease such as rheumatism may be the cause. However, scleral changes have been 
documented in Japanese literature, as summarized in Table 3: TAKANO 196627), YAMA-
NOUCHI and MISHIMA 196732), TANAKA 197029), OOTSUKI et al. 197 125). HIBINO and 
MIZUSAWA 19769), MINODA 197813), ODASHIMA and NIITSU 197824), YAMANOUCHI 
197833) , YAMANOUCHI et al. 197934) , KITANO et al. 198112) , and FUKAMACHI and HIKI-
  Table 2 Recurrence Rate due to Administration of Anti-neoplastic Drugs 
                          No. of Recurrence rate 
                         eyes thiotepa mitomycin C control 
Cassady 17 0 
Meacham 30 1 
Joselson & Muller 46 2.1 27.2 
Liddy & Morgan 26 4 
Asregadoo 102 6.8 
Kleis & Pico 48 8.3 31.3 
Kunitomo & Mori 31 16.1 
Mori et al. 89 13 
Nanba & Hisashige 40 7.4 
Yamashita & Adachi 28 35.7 
                     23 39 
                      23 43
Table 3 Scleral Lesion Due to Mitomycin C Instillation Pterygium Operation Summary of Literature
                                      Operation to Subjective Mitomycin C                                                                                                         ClinicalAuthor Age Sex Laterality O
nset (month) Complaints Solution Instillation Complications Management 
             27 
   Takano -Density- * 12 
  1966 0.4m9/ml 20 days scleral ulcer beta irradiation 
             10 
                                                                                                                         covering of 
   1968 51 M R 24 ocular pain 0.4mg/ml 4/day 1WK                                                                                        ay 1WK scleral ulcer conjunctiva    1968 
            2s 
*                                                   thinning of 3/day thinning of scleral homo-   Tanaka 
    1970 60 M R 12 sclera 0.4mg/ml 2 WK sclera graft covering     of conjunctiva 
         25 foreign body 
4/day scleral homo-Ootsuki et al. 46 F L sensation 0.2mg/ml scleral ulcer graft covering 
    1971 red eye 35 days of conjunctiva 
           0 R , L, scleral scleral homo-Hibi
no et al. 53 F R 36 calcification graft covering 
    1976 thinning of conjunctiva 
           28 scleral ulcer 
 Takatsuki 52 M 7 0.4mg/ml 4/day corneal ulcer 
   1978 1 WK iritis sec.                                                                                                      gla ucoma 
           20 scleral per-
   1978 10 3/day foration 1 WK endophthal-                                                                                          mitis 
          24 scleral thin-
Odashima & 64 F R 21 ocular pain 0.4mg/ml 4/day ning covering of 
Niitsu 1978 1 WK calcification conjunctiva                                                                                        i ritis 
            12 
Kitano et al. 52 F L 12 ocular pain 1/day scleral ulcer fascia late 
    1981 red eye 1 WK iritis hypopyon transplant
               53 M R 2 ocular pain 3/day scleral necroze           7 red eyer 0.4mg/ml 11 day iritis 
Fukamachi & 
Hikita 1981 * 
              44 M L 3 reduced vision 0.4mg/ml 3/day scleral perfo-                                                                                   1 WK ration uv itis 
                      * : Recurrent pterygium
TA 19817) . 
      According to these reports, the scleral lesions following administration of mitomy-
cin C after surgery for pterygium include scleral ulcer, scleral thinning, scleral calcifi-
cation, corneal perforation, scleral perforation, iritis, secondary glaucoma and endoph-
thalmitis. The duration from operation to onset of scleral lesion is between 7 months and 
3 years. Most occurrences were one or more years later. 
      According to KUNITOMO and MORI1"), exsudate on the wound surface begins to 
diminish after 1 week, owing to the topical application of mitomycin C, and the wound 
surface becomes paler than healthy areas after 12 to 14 days. In this area there is a po-
or vascular zone and inflammatory signs are not apparent. The sclera takes on a por-
celain-like appearance. This whitened area is considered the origin of the scleral lesion. 
     The early symptoms induced by mitomycin C instillation include allergic blepha l-
itis and blephalo-conjunctivitis associated with itching. About 1 week later, the patient 
may complain of ocular pain, foreign body sensation, red eye, headache, epiphora, pho-
tophobia and reduced vision. On slit-lamp examination, diffuse superficial keratitis, s-
cleral ulcer and iridocyclitis with aqueous flare, exsudate in the anterior chamber, pre-
cipitate and posterior synechiae are evident. These sysmtoms are regarded as a barome-
ter of intraocular detriment induced by mitomycin C and its application should be im-
mediately withdrawn. 
     The later symptoms are scleral thinning, ulcer, calcification and necrosis, corneal 
and scleral perforation, corneal ulcer, secondary glaucoma and endophthalmitis. These 
complications are severe and progressive. 
     Scleral thinning after mitomycin C instillation may be due to suppression of devel-
opment of collagen fiber in the process of wound healing. Mitomycin C inhibits the de-
velopment of granulation tissue and growth of the new vessel formation on the wound 
surface. Hence, scleral thinning indicates a decrease in fibrous connective tissue forma-
tion. 
     Calcification of the sclera was observed in 5 out of 9 patients we treated. The 
cause of this calcification was not clearly identified. Whether mitomycin C is directly 
related to the calcification of scleral collagen is unknown, but such cases of scleral cal-
cification are aften reported in the literature. These scleral damages rarely develop spon-
taneously, therefore, mitomycin C instillation after pterygium removal may become an 
important factor. 
     BLOOMFIELD et al.2) reported a case of acute corneal calcification in an uremic 
patient with corneal exposure and suggested that hypercalcemia, high calcium-phospho-
rus products, local increase in pH and local tissue damage helped to trigger rapid and 
dence calcification of soft tissues. They stated that the release of calcium and phospho-
rus from injured cells will increase the Ca-P products locally, and activation and/or re-
lease of cellular enzymes such as alkaline phosphatase, acid phosphatase and ATP-ase 
also may predispose to local calcification and that the corneal exposure will promote the 
calcification.
     TARR and CONSTABLE30) stated that factors contributing to radio-necrosis of 
sclera include surgical trauma, particularly cautery, scleral exposure, the influence 
of the damaged conjunctiva and tears, but not the dose of radiation. These factors are 
the same as those relating to mitomycin C instillation where the grade of operative invas-
ion of the sclera and the action of mitomcyin C on the sclera are important factors. The 
difference in the onset of scleral in our patients may be related to the surgical damage 
as well as the number and duration of mitomycin C instillations. In our patients, scleral 
calcification was observed in patients 56 to 73 years of age. Therefore, aging of the sc-
lera also may be a pertinent factor. YOKOYAMA36) noted 4 cases of scleral lesion out of 
57, due to mitomycin C instillation after pterygium excision. 
     MORI21> recommended the use of 0.2 mg/ml solution of mitomycin C, as this dose 
did not lead to a scleral lesion and there was no difference in recurrence rates, as com-
pared with the use of 0.4 mg/ml solution. However, scleral ulcer occurred 0.2 mg/ml 
solution of mitomycin C has been observed. Therefore, great care should be taken when 
prescribing mitomycin C solution, regardless of the dose. 
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